Ann: Letter to Shareholders, page-32

Fair summary of 2018, solid phase 2 trial results, successful presentation of data - understood and acknowledged by medical experts, validation of BIT225 development so far. BIOTRON has captured the attention of the wider (and financially superior) group in 2018.

One thing to note in the letter is that it takes time to convince big Pharmas that your product is worth investing in, these Pharmas need to understand why the drug is working the way it is, how it's unique and be 100% certain that they will be making a sound investment. With that requires alot more work and further tests to progess towards eliminating any doubts/concerns from potential investors/Pharmas.

What we and everyone (holders and non-holders) else following BIT know for certain is that BIT225 has a significant impact. The key now is to answer questions that potential Pharmas may have - that is done through progessive testing, presenting data to eliminate uncertainty and build a stronger case for BIT as a worthy investment option within the pool of drug developers.

The road may be a little more stretched than some may like (human nature), including myself, but slow and steady often leads to the desired outcome.

Daily charts and sentiment changes have no impact on the work in progress and final outcome, be patient and get rewarded. All IMO.

Hope you all have a great week and GLTAH.